In the univariable analysis, STS-PROM score (unadjusted OR (OR) 1.159; 95% CI 1.049 to 1.287; p=0.004), BNP levels on admission (OR 1.014; 95% CI 1.004 to 1.024; p=0.004 per 10 pg/mL increase), MS (OR 9.571; 95% CI 2.466 to 35.977; p<0.001) and invasive mAVPG improvement after TAVI (OR 1.048; 95% CI 1.015 to 1.086; p=0.006) were significantly associated with the new development of ADHF within 72 hours after TAVI. This evidence concerns the gene NPPB and myeloid sarcoma.